Cargando…
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib
ZD6474, a small molecule VEGFR and EGFR tyrosine kinase inhibitor, has been considered as a promising tumor-targeted drug in various malignancies. EGFR and cyclooxygenase-2 (COX-2) were found overexpressed in osteosarcoma in previous reports, so here we tried to explore the anti-osteosarcoma effect...
Autores principales: | Liu, Jiani, Wu, Jiangxue, Zhou, Ling, Pan, Changchuan, Zhou, Yi, Du, Wuying, Chen, Jie-min, Zhu, Xiaofeng, Shen, Jingnan, Chen, Shuai, Liu, Ran-yi, Huang, Wenlin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673269/ https://www.ncbi.nlm.nih.gov/pubmed/26050198 |
Ejemplares similares
-
ZD6474 – clinical experience to date
por: Heymach, J V
Publicado: (2005) -
Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011) -
Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma
por: Shen, J, et al.
Publicado: (2013) -
ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Freshney, R I
Publicado: (2007) -
ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
por: Mi, Y, et al.
Publicado: (2007)